Back to results
US 2026/0202418 A1Published application
Method of assessing risk of pml
AssigneeBiogen MA Inc.
InventorsGary Lewis BLOOMGREN, Carmen BOZIC, Sophia LEE, Amy PACE, Tatiana PLAVINA, Meena SUBRAMANYAM
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Claims20
1-21. (canceled)
A method of treating a subject in need thereof with an anti-VLA-4 therapy, the method comprising:
- a) determining an anti-JC virus (JCV) antibody titer in a biological sample from the subject, wherein the patient has been free of a non-anti-VLA-4-immunosuppressant therapy in the last 1, 3, 5 years or for the patient's lifetime, wherein the titer is determined to be at or below an index value of 0.9 in the sample;
- and
- b) administering an anti-VLA-4 antibody to the subject, thereby treating the subject with the anti-VLA-4 therapy,
- wherein the subject suffers from multiple sclerosis, a relapsing form of multiple sclerosis or inflammatory bowel disease.
1 more element
Dependencies are inferred from the claim text.